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Summary
Therapeutic interventions following severe traumatic brain
injury (TBI) are substantially influenced by complex and
interwoven pathophysiological cascades involving both,
local and systemic alterations. Our main duty is to prevent
secondary progression of the primary damage. This, in
turn, obliges us to actively search and identify secondary
insults related, for example, to hypoxia, hypotension, un-
controlled hyperventilation, anaemia, and hypoglycaemia.
During pharmacological coma we must rely on specific
cerebral monitoring which is indispensable in unmasking
otherwise occult changes. In addition, extended neuromon-
itoring (SjvO2, ptiO2, microdialysis, transcranial Doppler
sonography, electrophysiological studies, direct brain per-
fusion measurement) can be used to define individual
pathological ICP levels which, in turn, will support our de-
cision making. Extended neuromonitoring expands the lim-
ited knowledge derived from ICP and CPP values, thereby
allowing us to adequately adapt the type, extent and speed
of different therapeutic interventions. A more individual-
ised and flexible treatment concept depends on extended
neuromonitoring.
The present review addresses current evidence in favour
of extended neuromonitoring used to guide treatment op-
tions aimed at improving intensive care treatment of pa-
tients with severe TBI. With increasing experience gained
by the use of extended neuromonitoring in clinical routine
we may expect that the evidence obtained within the in-
dividual patient will translate to convincing evidence on a
larger scale for the entire study population.
Key words: critical care; evidence; monitoring;
pathophysiology; secondary brain damage; secondary
insults; treatment
Introduction
Severe traumatic brain injury (TBI) is associated with dra-
matic consequences for the individual patient and society,
especially if persisting deficits preclude successful reinteg-
ration [1, 2]. This, in turn, leads to a tremendous socio-
economic burden especially if young patients remain im-
paired, thereby being unable to contribute to the pension
programme.
Based on the predominant vulnerability of the injured brain
during the early posttraumatic phase and the fact that addi-
tional injuries during the acute and subacute phase strongly
determine quality of survival, prevention of secondary in-
sults is of utmost importance. Typical secondary insults
due to hypoxia, hypotension, uncontrolled hyperventila-
tion, hypoglycaemia as well as hypoventilation, hyperten-
sion, and hyperglycaemia must be actively looked for at all
time points. Contrary to the puristic approach, the extent of
additional injury cannot be assessed by relying on intracra-
nial pressure (ICP) and cerebral perfusion pressure (CPP)
alone. Extended neuromonitoring is important and may
even become indispensable in contemporary intensive care
treatment. Only with the help of extended neuromonitoring
are we able to unmask otherwise occult signs of cerebral
impairment, and most importantly, even at a normal ICP.
In addition, extended neuromonitoring will allow us to fine
tune quality and extent of our therapeutic interventions.
Contemporary continuous basic bedside neuromonitoring
consists of ICP and CPP. Extended bedside neuromonit-
oring comprises transcranial Doppler sonography (TCD),
jugular venous oxygen saturation (SjvO2), partial tissue
oxygen pressure (ptiO2), cerebral microdialysis to assess
changes in cerebral metabolism (glucose, lactate, pyruvate,
glutamate, glycerol), perfusion measurement, and electro-
physiological studies including electrocorticography to un-
mask cortical spreading depression (CSD).
This review article will provide a detailed insight into
neuromonitoring-guided treatment options aimed at pre-
venting and reducing brain damage following severe TBI,
focusing on the questions:
– How can we unmask cerebral impairment during
pharmacological coma?
– What is the impact of extended neuromonitoring in
routine intensive care?
– What is the level of evidence and what is to be expected
for the future?
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How can we unmask cerebral
impairment during pharmacological
coma?
In clinical routine, different non-invasive and invasive
monitoring methods are indispensable to unmask otherwise
occult changes. Only then can we guide the type, extent
and duration of specific therapeutic interventions (table 1).
Based on the fact that traumatic lesions such as haemor-
rhages, contusions and oedema already exhibit a stereotyp-
ic growth pattern during the first hours after injury, spe-
cific neuromonitoring must be used early after TBI. It is
also important to install extended neuromonitoring during
phases with normal ICP <15 mm Hg during pharmacolo-
gical coma allowing to unmask pathological processes and
aimed at reducing progression of secondary brain damage.
The different techniques are associated with certain disad-
vantages summarised in table 2. Given the regional hetero-
geneity found under normal anatomical and physiological
as well as pathological conditions a combination of para-
meters assessing global as well as local changes appears
useful. In this context, SjvO2 reflects global changes while
ptiO2 unmasks local alterations. To date, the location of
the different probes is still discussed controversially. The
ideal target area must be considered individually, knowing
that monitoring of a normal area could result in missing
episodes requiring therapeutic interventions while monitor-
ing within a pathologic area could lead to excessive treat-
ment possibly being less beneficial for the adjoining tis-
sue. Furthermore, insertion of more probes which would
allow assessment of dynamic changes in different regions
is associated with an increased risk of additional injury,
a substantial cost factor, and a certain risk of confusing the
samples and values.
Intracranial pressure
The primary parameter used to judge cerebral deterioration
is ICP. Elevated ICP due to increased intracranial volume
induces new and progressing secondary damage which, in
turn, can induce and maintain a vicious circle [3]. The over-
simplified understanding that increased ICP >20 mm Hg
is pathologic lead to the current misconception that normal
ICP guarantees absence of pathologic processes. Exten-
ded neuromonitoring, however, shows that this is incorrect.
New data show that metabolic and functional alterations
even precede increases in ICP following TBI [4]. It is
important to remember that this threshold of 20 mm Hg
stems from a time of insufficient neuromonitoring as ex-
tended neuromonitoring (e.g., SjvO2, ptiO2, microdialysis,
and TCD) had not been integrated in daily routine. A very
simple measure to indirectly estimate global cerebral perfu-
sion is to calculate cerebral perfusion pressure (CPP): CPP
= MABP- ICP. A “normal” CPP, however, does not guaran-
tee sufficient cerebral perfusion and oxygenation. To define
an optimal CPP, other parameters as e.g., ptiO2, SjvO2,
metabolism, and flow velocity are helpful. ICP measure-
ment requires a surgical intervention which is associated
with certain risks as e.g., bleeding, additional brain dam-
age, infections. Furthermore, regional heterogeneity, influ-
ence of extent of midline shift, and the routine measure-
ment confined to the supratentorial compartment are cer-
tain limitations [5]. As shown by Rosner et al. [6] ICP-
dependent changes in CPP are dynamic, therefore requiring
therapeutic flexibility, a fact which is regularly overlooked.
Jugular venous oxygen saturation (SjvO2) and arterio-
jugularvenous differences
Cannulation of the internal jugular vein allows analysis of
SjvO2, calculation of various metabolic indices (e.g. oxy-
gen- glucose index: OGI, lactate- oxygen index: LOI, lact-
ate- glucose index: LGI) [7, 8], determination of the oxy-
gen extraction ratio (OER) and assessment of, for example,
arterio- jugular venous lactate difference. These different
parameters enable detailed assessment of cerebral energetic
disturbances [8]. SjvO2 reflects changes in cerebral oxygen
supply, cerebral perfusion and cerebral oxygen consump-
tion as SjvO2 correlates directly with perfusion and correl-
ates inversely with cerebral oxygen consumption. Thus, an
increase in MABP with subsequent amelioration of CPP
as well as reduced hyperventilation will improve cerebral
oxygen supply due to pressure-dependent and vasodilation-
mediated increased perfusion. Reducing cerebral oxygen
consumption due to pharmacological inhibition of neuronal
activity during pharmacological coma or by reducing brain
temperature will also elevate SjvO2.
Table 1: Neuromonitoring: areas of interest, implications and guidance of treatment options.
Monitoring Area of
interest
Implications Guidance of treatment options
intracranial pressure (ICP) focal/
global
increase in intracranial volume and pressure hyperventilation, blood pressure support, analgesia/
sedation, body positioning, temperature
cerebral perfusion pressure (CPP) global Indirect assessment of cerebral perfusion blood pressure support
SjvO2 global global cerebral perfusion and oxygenation ventilation, oxygenation, CPP, analgesia/sedation,
temperature, transfusion
ptiO2 focal local cerebral perfusion and oxygenation ventilation, oxygenation, CPP, analgesia/sedation,
temperature, transfusion
microdialysis focal local cerebral metabolism, perfusion, oxygenation,
glucose supply, mitochondrial function
glucose: glucose supply
lactate: anaerobic metabolism
lactate to pyruvate ratio: mitochondrial dysfunction,
severe metabolic impairment
glutamate: excitation
glycerol: cell membrane damage
ventilation, oxygenation, CPP, analgesia/sedation,
temperature, transfusion, nutritional support
TCD focal cerebral perfusion: low flow, hyperaemia, vasospasm ventilation, CPP, analgesia/ sedation, transfusion
Electrocorticography focal local cortical spreading depression sedation, CPP, nutrition (glucose)
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Global cerebral changes as reflected by SjvO2 correlate
well with local measurements using ptiO2 [9]. SjvO2 ≤50%
reflect cerebral ischaemia and should be avoided. Immedi-
ate correction is important [10] since hypoxic/ ischaemic
SjvO2 values are associated with metabolic perturbation re-
flected by increased lactate and glutamate levels [11] as
well as sustained mortality and morbidity [12].
SjvO2 values >80% reflect underlying hyperaemia or lux-
ury perfusion which permits a reduction in CPP and a de-
crease in cerebral vasodilation by controlled hyperventila-
tion.
The impact of calculating arterio- jugular venous lactate
difference is less clear and convincing [13, 14], possibly
due to the fact that the brain is capable of consuming lactate
to produce energy under pathological conditions [15].
Cannulation of the jugular vein is associated with certain
risks such as, for example, haemorrhage and puncture of
the carotid artery if not controlled by sonography, throm-
bosis formation and catheter-related infections possibly
progressing to sepsis. In addition, the side of insertion rel-
ative to the traumatic lesions has been discussed controver-
sially.
Tissue oxygenation- ptiO2
Assessing ptiO2 unmasks both local changes and the cereb-
ral consequences of systemic influences, thereby allowing
guidance of the type and extent of therapeutic interventions
[9, 16]. Similar to changes in SjvO2, ptiO2 values indirectly
reflect cerebral perfusion and oxygenation [17]. Low SjvO2
and ptiO2 values unmask reduced cerebral perfusion due to,
for example, systemic hypotension or local cerebral vaso-
constriction caused by hyperventilation or vasospasm. Fur-
ther reasons such as sustained oxygen consumption due to
increased neuronal activity resulting from insufficient an-
algesia/ sedation, epileptic discharges, insufficient oxygen
supply due to anaemia, impaired cardiac output, and in-
sufficient oxygenation must be searched for and corrected.
Thus, assessing global as well as local changes reflected by
SjvO2 and ptiO2 permits detailed and controlled therapeutic
corrections. In this context, we can decide whether, for ex-
ample, ventilation, haemodynamic support or haematocrit
must be corrected.
Validation studies have shown that ptiO2 values <10 mm
Hg (Licox®) reflecting tissue hypoxia are associated with
increased extracellular glutamate if not corrected within 30
minutes [18, 19]. In addition, these ischaemic values cor-
relate with neuropsychological deficits in survivors [20].
As summarised by Maloney- Wilensky and colleagues
Table 2: Advantages and disadvantages of the different neuromonitoring tools used to guide type, extent, and duration of treatment options.
Monitoring Advantages Disadvantages
Intracranial pressure (ICP) • continuous assessment of intracranial pathology • local measurement
• regional heterogeneity
• only supratentorial compartment
• surgical intervention with potential for additional brain damage
(haemorrhage, injury of deep structures, infections)
• incorrect values following craniectomy, subdural air entrapment and
absent wave curve
Cerebral perfusion pressure (CPP) • continuous assessment of cerebral perfusion
equivalent
• calculated value
• estimated global perfusion
• no assessment of regional perfusion
• impossible without ICP
SjvO2 • (continuous) assessment of cerebral oxygenation/
perfusion
• discontinuous assessment
• requires blood sampling
• limited stability of sensors for continuous assessment of oxygen
saturation
• requires cannulation with associated risks (bleeding, thrombosis,
bacteraemia, infections)
• impaired venous outflow with increased ICP
ptiO2 • continuous assessment of cerebral oxygenation/
perfusion
• local measurement
• regional heterogeneity
• surgical intervention requiring trephination with potential for additional
brain damage (haemorrhage, injury of deep structures, infections)
• expensive
Microdialysis • discontinuous assessment of cerebral metabolism/
indirect assessment of cerebral perfusion and
oxygenation
• local measurement
• regional heterogeneity
• surgical intervention requiring trephination with potential for additional
brain damage (haemorrhage, injury of deep structures, infections)
• expensive
TCD • indirect assessment of cerebral perfusion
• indirect assessment of ICP via calculated pulsatility
index
• discontinuous
• requires expertise
• requires additional investigations to differentiate vasospasm from
hyperaemia (e.g., angiography, MRI, ptiO2, SjvO2, microdialysis)
Electrocorticography • continuous assessment of electrical discharges • local measurement
• regional heterogeneity
• surgical intervention requiring trephination and opening of the dura with
potential for additional brain damage (haemorrhage, cortical injury,
infections)
• expensive
• not widely performed
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ptiO2 <10 mm Hg longer than 15 minutes is associated with
worse outcome and increased mortality [21]. Taken togeth-
er, these findings suggest that integrating continuous as-
sessment of ptiO2 in daily routine could be valuable in the
prevention of overlooking situations with impaired cereb-
ral perfusion and oxygenation. To date, we still lack a
clear consensus on how to correct decreased ptiO2 values
and which sequence is the most appropriate as several ap-
proaches can be used, including increases in FiO2, CPP,
paCO2, sedation and haemoglobin. In addition, it is unclear
which target level should be used and if excessive or inad-
equate correction is harmful.
Abnormally elevated ptiO2 values >30 mm Hg (corres-
ponding to SjvO2 ≥80%) strongly suggest uncoupling of
cerebral metabolism from cerebral perfusion. In this con-
text, reduced cerebral oxygen consumption, for example,
due to deep sedation is associated with strong vasodilation
leading to hyperaemia and global luxury perfusion. Hyper-
aemia, in turn, elevates ICP caused by an increase in intra-
cranial blood volume [22].
Cerebral microdialysis
Cerebral microdialysis allows detailed insight into other-
wise hidden metabolic alterations by measuring changes in
glucose, lactate, pyruvate, glycerol, glutamate, and calcu-
lating lactate to pyruvate ratio [23, 24]. Due to the dialysis
duration which is commonly 60 minutes, clinical decisions
are based on metabolic changes which have already oc-
curred previously. Consequently, the metabolic alterations
unmasked by microdialysis should always be judged to-
gether with other parameters which are assessed continu-
ously such as ptiO2, SjvO2, CPP, ICP. Continuous glucose
analysis using microdialysis is currently being investig-
ated.
To avoid injuries within the pre- and postcentral cortex, mi-
crodialysis (as well as ptiO2 and ICP) are inserted in the
frontal lobe. Similar to the regional heterogeneity of inter-
hemispheric pressure gradients we also find regionally dif-
ferent metabolic changes [25]. Nonetheless, signs of im-
paired cerebral metabolism are found even in regions
without obvious signs of structural damage. This functional
impairment can result from increased ICP due to local
changes and can be induced by systemic influences due to,
for example, hypotension, hyperaemia, vasospasm, hyper-
ventilation, fever, epileptic discharges, hypoglycaemia or
anaemia. In addition, improvement of signs of metabolic
deterioration can be used to reflect positive therapeutic ef-
fects [26]. Integration of microdialysis allows reduction of
CPP in a controlled manner to 50 mm Hg as practiced with-
in the “LUND- concept” [27]. In addition to absolute val-
ues and relative changes of the different metabolic para-
meters over time, calculating lactate to pyruvate ratio re-
flects the severity of underlying metabolic impairment
[28]. Pathologically increased lactate to pyruvate ratios are
associated with subsequent chronic frontal lobe atrophy
[28].
Elevated extracellular glutamate reflects excessive neuron-
al excitation or signs of severe cell damage resulting in re-
lease of intracellularly stored glutamate. Increased lactate
levels exhibit an energetic deficit while decreasing gluc-
ose levels can result from increased cellular uptake and
metabolism and/or insufficient supply due to systemic hy-
poglycaemia, impaired perfusion, or insufficient expres-
sion of glucose transporters. Elevated glycerol values re-
flect membrane damage.
Overall, microdialysis can be used to unmask pathological
changes, characterise pathological relevance of certain al-
terations, and guide therapeutic interventions (e.g. hyper-
ventilation, oxygenation, sedation, CPP level). As recently
shown by Timofeev and colleagues low glucose and elev-
ated lactate to pyruvate ratios are significant independent
predictors of mortality [29]. Metabolic changes determined
by microdialysis can even be used as an early warning sys-
tem to unmask pathological alterations which precede in-
creases in ICP by 12 hours [4, 19].
Taken together, these findings suggest that integrating
monitoring of cerebral metabolism in daily routine could
be valuable in the detetion of functional deterioration with
subsequent oedema formation and increase in ICP. To date,
we still lack a clear consensus on the threshold values re-
quired to prompt corrective measures, including increases
in FiO2, CPP, paCO2, sedation, haemoglobin and glucose.
In addition, it is unclear which target level should be used
and if excessive or inadequate correction is harmful.
Transcranial Doppler/ Duplex sonography
Since its introduction in clinical routine, transcranial Dop-
pler sonography (TCD) has proven helpful in unmasking
conditions of low flow [30], vasospasm and hyperaemia
all of which require differential therapeutic interventions.
TCD- determined cerebral blood flow velocity within the
large basal cerebral arteries reflects regional cerebral per-
fusion, cerebral autoregulation, CO2- reactivity under nor-
mal and pathological conditions [31]. In addition to abso-
lute flow velocities calculated values, such as the pulsatility
index (PI) and resistance index (RI) allow non-invasive es-
timation of ICP and CPP [32, 33], providing individual
anatomy allows sufficient insonation depth. This approach
is helpful if an ICP probe cannot be inserted due to a co-
agulation disorder or if an ICP probe is damaged, thereby
bridging the time until a new probe is inserted. However,
this non- invasive assessment of ICP is not a substitute for
continuously measured ICP.
Electrophysiological studies:
electroencephalogram (EEG),
evoked potential (EP), cortical
spreading depression
EEG and EP
Functional changes in neuronal activity and transmission
of axonal information can be assessed by EEG, sensory
evoked potentials (SEP) or acoustic evoked potential
(AEP). These investigations require specialised and well-
trained personnel. Changes within the different EEG fre-
quency spectra and amplitudes are also influenced by the
lesions themselves, concomitant analgesia/ sedation, hypo-
thermia and hyperventilation. Whilst pathological changes
in evoked potentials reliably predict mortality and morbid-
ity [34] this is not the case for EEG analysis as the under-
lying pharmacological coma influences the different fre-
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quency bands. Apart from diagnosing epileptic discharges,
EEG is commonly used to adapt the dose of barbiturates
aimed at maintaining a burst suppression pattern during
barbiturate coma. More detailed analysis of the shifts with-
in the frequency bands has shown that post traumatically
reduced variability of the alpha frequency is gaining in-
creasing prognostic importance as this is associated with
significantly reduced regeneration [35. 36]. Simplified
EEG analysis (BIS® EEG, Narcotrend®) can be used to
continuously assess and control sedation. The application
of these techniques in the clinical intensive care routine still
awaits indepth analysis.
Cortical spreading depression (CSD)
CSD resulting from neuronal and glial depolarisation is a
progressive functional disturbance associated with energy
consuming processes [37], thereby contributing to the sec-
ondary growth of a pre-existing lesion that is of clinical rel-
evance [38, 39]. CSD is caused by elevated extracellular
potassium concentrations, decreased cerebral NO levels
and reduced blood and brain glucose concentrations [40,
41]. Measurement of CSD requires subdural introduction
of a special sensor directly placed on the cortical surface.
CSD is associated with decreased cerebral glucose, in-
creased lactate to pyruvate ratio and elevated lactate [42,
43]. Further investigations are required to determine if a
decrease in glucose with an increase in lactate to pyruvate
ratio is specific for CSD. This would allow identification
of CSD based on metabolic changes using microdialysis.
Assessment of CSD requires surgical insertion and sub-
dural placement of specialized sensors which is currently
only performed in specialised centers. This surgical inter-
vention is also associated with certain risks such as subdur-
al haematoma and infections.
Thermal diffusion flowmetry (Bowman Perfusion
Monitor®)
Specialized probes positioned within the brain tissue allow
determination of local cerebral blood flow (CBF) based
on the difference in temperature between the neutral plate
and the heated element. Changes in CBF can be used to
diagnose impaired perfusion and disturbed autoregulation,
thereby allowing guidance of treatment options such as hy-
perventilation and blood pressure variation [44, 45]. As
with the other probes, interpretation of CBF values is con-
fined to a small region of interest. In case of fever, accuracy
of the temperature- dependent readings is questioned. In
addition, surgery- associated complications must also be
considered (additional tissue damage, bleeding, infection).
What is the impact of extended
neuromonitoring in routine intensive
care?
Basic treatment aims in patients suffering from severe TBI
are to optimise cerebral perfusion, improve oxygenation
and stabilise metabolism in order to prevent secondary pro-
gression of underlying brain damage. For this, integration
of extended neuromonitoring in our daily clinical routine
appears helpful. Extended neuromonitoring may provide
more detailed insight into otherwise occult changes. For
this, SjvO2, ptiO2, microdialysis, TCD and electroenceph-
alographic studies provide important data enabling charac-
terisation of functional influences defining threshold val-
ues and the adaption of therapeutic interventions in type,
extent and duration (fig. 1). These monitoring modalities
aid in preventing excessive therapeutic corrections which
by themselves can induce additional damage. In this con-
text, aggressive volume administration to increase CPP has
been associated with a sustained risk of ARDS [46] and
abdominal compartment syndrome [47], excessive ventil-
atory support to increase paO2 is feared to induce addition-
al pulmonary damage [48], aggressive lowering of arteri-
al blood glucose to prevent hyperglycaemia- induced cell
damage increases frequency and extent of hypoglycaemic
episodes [49], and a categorical transfusion regimen to im-
prove cerebral oxygenation is offset by transfusion- related
complications [50].
Basic neuromonitoring limited to ICP and CPP cannot as-
sess changes in cerebral perfusion, oxygenation, metabol-
ism and electrophysiological function. Consequently, we
are bound to not only miss important signs of deterioration
but we will also fail to adapt and reduce therapeutic in-
terventions once previous impairment has been corrected.
There is increasing evidence that extended neuromonitor-
ing can be used to:
– identify optimal CPP
– guide ventilatory support: oxygenation and ventilation
– define adequate haemoglobin level and guide transfusion
practice
– determine optimal blood and brain glucose
– guide decompressive craniectomy
Figure 1
Illustrative lateral X- ray view showing positioning of ICP, ptiO2,
microdialysis (MD), and jugular venous catheter allowing
measurement of SjvO2. This allows to combine local (ptiO2,
microdialysis) with global neuromonitoring (SjvO2).
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Guidance of CPP
As already shown by Rosner and colleagues, the optimal
CPP defined by the lowest ICP must be identified within
each patient [51] and is subject to a strong intra- and in-
terpatient variability even within a single day. According
to the original description, optimal CPP was 90 mm Hg.
Whether this also resulted in a CPP- dependent improve-
ment of cerebral perfusion, oxygenation and metabolism
cannot be determined as extended neuromonitoring had not
been integrated in this study. As shown by Reinert and
colleagues, ptiO2 is strongly influenced by CPP [26]. This
was also corroborated by Marin-Caballos and colleagues
nicely demonstrating that ptiO2 values can be used to de-
termine the lower most acceptable CPP threshold [52]. The
authors convincingly concluded that the generally recom-
mended CPP threshold of 60 mm Hg is insufficient. This
is in line with other reports showing that low and even
“normal” CPP values cannot protect from cerebral hypox-
ia reflected by ptiO2 measurements and signs of impaired
metabolism [24]. This underscores the necessity of con-
tinuously assessing ptiO2 and cerebral metabolism. In this
context, a normal CPP of approximately 70 mm Hg has
been shown to be insufficient for the perifocal tissue com-
pared to normal appearing tissue in which ptiO2 was signi-
ficantly higher [53]. CPP exceeding 75 mm Hg is required
to induce highest ptiO2 values [26]. Integrating ptiO2 in
clinical routine using a ptiO2- guided treatment protocol
in addition to ICP and CPP significantly improved ptiO2
levels, kept ICP <20 mm Hg, maintained CPP at stable val-
ues (mean 76 mm Hg), improved outcome reflected by the
Glasgow Outcome Scale and reduced mortality rate com-
pared to the standard ICP/ CPP- directed therapy [54]. Sim-
ilar findings were also reported by Spiotta and colleagues
[55]. Mortality was linked to longer durations of com-
promised brain oxygen (ptiO2 <20 mm Hg), brain hypoxia
(ptiO2 <15 mm Hg), more episodes and longer cumulative
duration of compromised ptiO2 values and less successful
treatment of compromised ptiO2 [55].
As shown by Nordström and colleagues it is of the utmost
importance to focus not only on an individual parameter
but to also consider concomitant therapy. Bearing this in
mind reduction for example, of the CPP to 50 mm Hg is
possible but cannot and should not be extended to all pa-
tients, especially if the appropriate neuromonitoring, e.g.
cerebral microdialysis is not used [27]. In this context, lact-
ate and the calculated lactate to pyruvate ratio reliably re-
flect insufficient cerebral perfusion and oxygen delivery re-
sponsible for energetic and metabolic impairment [27, 56].
Improvement in cerebral perfusion and correction of an-
aemia successfully normalised brain lactate to pyruvate ra-
tio, glycero, and glutamate concentrations [56].
Guidance of ventilatory support:
oxygenation and ventilation
As in all critically ill patients lung protective ventilation
is recommended to avoid lung injury and haemodynamic
instability. Ventilatory settings are adjusted according to
pre-defined paO2 and paCO2 targets. The paO2 and paCO2
targets, in turn, can be set by ptiO2 and SjvO2. This pre-
vents excessive increase in FiO2, PEEP and ventilation fre-
quency.
Oxygenation. Even during deep sedation and hypothermia,
the metabolically active brain requires sufficient amounts
of oxygen to fuel energy-consuming processes. For this,
we require sufficient cardiac output, optimal local perfu-
sion, adequate haemoglobin concentration and sufficient
pulmonary function to enable ideal oxygen transport and
cerebral oxygen supply. Under conditions of controlled hy-
pothermia and pharmacological coma cerebral oxygen con-
sumption is decreased. Thus, a categorical paO2 level dic-
tating the ventilatory support might be inadequate as it
promotes aggressive ventilatory settings. Cerebral oxygen-
ation using ptiO2 and SjvO2 are very helpful in guiding
ventilatory support.
As shown under clinical conditions, an increase in FiO2
significantly increased ptiO2 [26, 57] and reduced cerebral
lactate [26]. Interestingly, a too aggressive increase in ptiO2
using normobaric hyperoxia (FiO2 1.0) was associated with
decreased cerebral blood flow despite improved brain
metabolism and coincided with worse outcome three
months after TBI. As shown under experimental condi-
tions, increasing oxygen supply alone is insufficient to im-
prove cerebral oxygenation if impaired cerebral perfusion
is not corrected [58].
Positive end expiratory pressure (PEEP). Elevated PEEP
can induce pulmonary and circulatory impairment, espe-
cially during hypovolaemia by impairing venous backflow
to the heart, thereby resulting in secondary reduced pul-
monary perfusion with worse blood oxygenation. In addi-
tion, increased PEEP can contribute to elevated ICP due
to impaired cerebral venous outflow and can also reduce
mean arterial and cerebral perfusion pressure, thereby im-
pairing cerebral perfusion and oxygenation [52, 59].
Hyperventilation. Uncontrolled and prophylactic hyper-
ventilation during the first days following TBI induces ad-
ditional secondary ischaemic brain damage [60] and must
be avoided meticulously. Hypocapnia-induced vasocon-
striction mediates impaired perfusion, metabolic and
neurochemical alterations as reflected by reduced ptiO2
and SjvO2 and elevated extracellular glutamate and lactate
[61]. Interestingly, even small changes in paCO2 from 38
to 34 mm Hg within normal limits are detrimental [62].
Consequently, extended neuromonitoring should also be
performed in patients during anticipated normoventilation.
Hyperventilation is an easy and helpful therapeutic inter-
vention to decrease elevated ICP [63]. However, we should
control hyperventilation by using appropriate neuromonit-
oring techniques to unmask signs of cerebral ischaemia due
to hyperventilation-induced vasoconstriction because nor-
mal ICP levels achieved by hyperventilation will cause us
to miss relevant pathological processes within the brain.
This can only be prevented by integrating appropriate neur-
omonitoring. Reduced SjvO2, ptiO2 and signs of metabolic
impairment (lactate, glutamate, lactate-to-pyruvate ratio)
[64, 65] aid in assessing the lowest possible paCO2 level
[66–69] and avoid active induction of secondary brain
damage.
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Guidance of haematocrit and
transfusion requirements
To prevent insufficient cerebral oxygenation adequate oxy-
gen supply must be maintained. For this, an appropriate
number of oxygen carriers, i.e. red blood cells and haemo-
globin must be present. At present, it still remains unclear
which haemoglobin count is optimal in patients with severe
TBI. From a physiological point of view the haematocrit
is optimal whenever the tissue is sufficiently supplied with
oxygen without reducing perfusion due to increased viscos-
ity. Inducing acute haemodilution with a haematocrit <21%
under experimental conditions was detrimental [70]. In pa-
tients with pre-existing vasospasm following ruptured an-
eurysmal bleeding, active reduction in haematocrit from 36
to 28% resulted in significantly reduced cerebral oxygen
supply [71]. Thus, any form of severe haemodilution
should be avoided. Whether a gradual and slow decrease in
haematocrit developing over days as observed under clinic-
al conditions following severe TBI will also impair cereb-
ral oxygenation and metabolism remains unclear. Concom-
itant therapy due to hypothermia and deep sedation could
increase the hypoxic threshold, thereby allowing a lower
haematocrit level and thus decreasing transfusion require-
ment. Under controlled critical care conditions with stable
CPP and stable oxygenation and ventilation, ptiO2 can be
used to define the transfusion threshold [72, 73]. Patients
with a ptiO2 >15 mm Hg do not profit from red blood cell
transfusion [73]. Only in patients with a haematocrit <30%
did a transfusion of red blood cells persistently increase
ptiO2 >15 mm Hg, providing ptiO2 was below 15 mm Hg
[73]. Concomitantly, CPP must be maintained above 60
mm Hg to prevent cerebral hypoxia determined by ptiO2
due to low haemoglobin levels [74]. These data show that
ptiO2 and brain metabolic parameters can be used to con-
tinuously assess critical transfusion threshold. Adapting the
transfusion threshold based on a neuromonitoring-guided
approach is expected to enable us to determine the correct
time point and amount of transfusion of red blood cells,
thereby avoiding categorical and even inadequate transfu-
sion practice. The impact of neuromonitoring-guided trans-
fusion practice on morbidity and mortality is currently be-
ing investigated in more detail.
Guidance of optimal blood and brain
glucose values
Elevated blood glucose >9.4 mmol/l (>169 mg/dl) is as-
sociated with increased mortality and morbidity [75, 76].
Hyperglycaemia induces mitochondrial damage, aggrav-
ates oxidative stress, impairs neutrophil function, reduces
phagocytosis, and diminishes intracellular destruction of
ingested bacteria. These destructive cascades can be pre-
vented by fast normalisation of elevated blood glucose
levels. Maintaining blood glucose levels within tight limits
between 4.4 and 6.1 mM (80 to 110 mg/dl) [77], however,
is off-set by the risk of hypoglycaemia and strong variation
in blood glucose levels [78]. The increased frequency of
hypoglycaemia during the first days following injury was
associated with sustained mortality [79–81]. As shown by
Vespa and co-workers reducing blood glucose levels to
4.4–6.1 mmol/l significantly increased extracellular
glutamate levels and augmented lactate to pyruvate ratio,
reflecting excessive neuronal excitation and metabolic per-
turbation [82]. In addition, mortality was increased in pa-
tients with decreased blood glucose and low cerebral extra-
cellular glucose levels [83]. Under experimental and clin-
ical conditions blood glucose levels <5 mmol/l can induce
CSD [84–88]. Thus, any correction to low normal blood
glucose values should be tightly controlled by extended
neuromonitoring. In this context, jugular venous paramet-
ers reflected increased cerebral oxygen consumption, lact-
ate and CO2 production and decreased glucose uptake at
low blood glucose levels with signs of improvement at ar-
terial blood glucose levels between 6 and 9 mmol/l [6].
With the help of cerebral microdialysis the influence of in-
sulin administration on brain metabolism can be charac-
terised. In this context, insulin should not be given at ar-
terial blood glucose levels <5 mmol/l as this significantly
increased extracellular glutamate and lactate to pyruvate
ratio while insulin administration is encouraged at arterial
blood glucose levels >9 mmol/l to increase cerebral gluc-
ose levels and reduce lactate to pyruvate ratio [86, 87]. Op-
timal and safe blood glucose levels appear between 6 and
9 mmol/l. Cerebral microdialysis also helps in assessing
optimal brain glucose levels. Brain glucose should remain
above 1 mmol/l as brain glucose levels <1 mmol/l are as-
sociated with signs of metabolic impairment as reflected
by increased lactate to pyruvate ratio [86–88]. Persistently
low brain glucose levels were associated with electrograph-
ic seizures, non-ischaemic reductions in cerebral perfusion
pressure, decreased jugular venous oxygen saturation, in-
creased glutamate levels, and poor outcome [88]. Integrat-
ing brain glucose measurements in clinical routine has al-
lowed us to optimise nutritional support to correct cerebral
Figure 2
Illustrative case showing that brain and subcutaneous glucose are
influenced by enteral and parenteral nutrition. Following cessation
of enteral nutrition, brain glucose dropped below 1 mmol/ l.
Restarting enteral nutrition corrected cerebral hypoglycaemia.
Developing constipation prohibited increase in enteral nutrition.
Parenteral nutrition was begun to prevent caloric deficiency and to
prevent cerebral hypoglycaemia. Overall, changes in brain glucose
are also reflected by subcutaneous glucose which reflects changes
in arterial blood glucose (not shown). However, subcutaneous
glucose did not unmask cerebral hypoglycaemia after stopping
enteral nutrition. These changes occurred at ICP values <15 mm
Hg which were maintained due to aggressive treatment consisting
of deep sedation, controlled mild hypothermia (35°C), and
controlled ventilation.
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hypoglycaemia by increasing arterial blood glucose levels.
This can be achieved by optimising enteral or parenteral
nutrition (fig. 2). If this will also translate to an improved
outcome remains to be shown.
Guidance of decompressive
craniectomy
Intracranial hypertension impairs cerebral perfusion, oxy-
genation and metabolism. Decompressive craniectomy, in
turn, will improve cerebral perfusion, oxygenation and
metabolism which is most effective with dura enlargement
[89–94]. The presence of pathological neuromonitoring be-
fore clinical deterioration [92] underscores the importance
of integrating extended neuromonitoring in clinical routine.
Consequently, extended neuromonitoring can aid in decid-
ing when to perform a decompressive craniectomy [93].
It remains to be shown if extended neuromonitoring may
be helpful in identifying the appropriate patients, thereby
avoiding an increase in unfavourable outcome despite suc-
cessfully treating intracranial hypertension as recently
shown by Cooper et al. [94].
What is the level of evidence and what is to be expected
for the future?
The best of knowledge expressed in the maxim of
evidence-based medicine requires clinically convincing
and statistically sound data. In this context double blind,
placebo-controlled, multicentre, international clinical trials
are far superior to meta-analyses, systematic reviews, retro-
spective analyses, and expert opinions or individual exper-
ience. None of the techniques, including the non-invasive
and continuous measurement of peripheral oxygen satur-
ation (SpO2) as commonly used in daily clinical routine,
have ever been investigated in a double blind, placebo-con-
Figure 3
Three- dimensional graph showing functional impact of blood
glucose and cerebral perfusion (indirectly assessed by ptiO2) on
brain glucose. While low blood glucose can be compensated by a
higher level of cerebral perfusion (higher ptiO2 values) to increase
brain glucose levels, elevated blood glucose can compensate for
lower level of cerebral perfusion (lower ptiO2 values). Optimal
conditions unmasked by highest brain glucose levels appear to be
at arterial blood glucose values between 8 and 9 mmol/l and ptiO2
values around 30 mm Hg.
trolled, multicentre, international clinical trial with the aim
of proving their importance in reducing mortality and im-
proving outcome. Given ethical considerations it will not
be possible to conduct a double blind, placebo-controlled
clinical trial in which patients will be deprived of a certain
neuromonitoring technique, as positive findings have been
observed in individual patients and retrospective analyses.
For a reliable interpretation and conduction of clinical trials
evaluating the level of evidence for any technique requires
an adequate level of experience. To gain this adequate level
of experience, in turn, sufficient time and number of pa-
tients are required. Objectively seen, we are still midst in
a learning phase and cannot assume that the current know-
ledge is set in stone as reflected by the steadily growing
number of publications investigating the usefulness of ex-
tended neuromonitoring in clinical diagnostics and therapy.
In addition, in depth knowledge is required. We must real-
ize that the underlying pathophysiological interactions and
circuits are multi- dimensional and that focusing on only
one parameter is wrong. In this context, brain glucose, for
example, is strongly influenced by blood glucose and per-
fusion (indirectly reflected by ptiO2) (fig. 3). Blood gluc-
ose as well as perfusion are influenced by other interven-
tions which must also be considered. At the same time,
oversimplification of very complex problems for facilit-
ated integration in clinical routine must be avoided. This
can only be provided by specialists. To make interpretation
of the obtained data even more complicated we pretend to
already have found the optimal treatment form when only
focusing on one parameter. In reality, however, the con-
flicting impact, i.e. both, positive and negative, of our con-
temporary routine treatment is unclear. Although we are
lacking a scientifically sound basis, we are convinced that
we treat our patients to their benefit based on our cur-
rent knowledge and experience. From a scientific point of
view and in face of our duty to improve current intens-
ive care medicine, it is unfair and not justified to down-
grade the different techniques of extended neuromonitor-
ing. Ongoing as well as future investigations will improve
our understanding and subsequently the fine-tuning of our
treatment options. At present, the level of evidence is con-
vincing for the experienced specialists and doubtful for the
sceptics and those who are not familiar with these tech-
niques. The future will show us which of the techniques
are “nice to have” and which must be considered essen-
tial. Based on my personal experience it has become very
difficult for me to adequately treat patients without para-
meters reflecting cerebral oxygenation/ perfusion and brain
metabolism. In clinical routine I do not base my decisions
solely on changes in ICP and CPP. Downstream parameters
are always used to define the optimal ICP and CPP level
on an individual basis. With the integration of extended
neuromonitoring we were able to significantly reduce the
amount of transfused red blood cells and diminish the rate
of acute lung injury due to excessive volume administra-
tion.
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